WCLC 2015 Evaluation

Page 1 of 3

WCLC 2015 Evaluation
Completion is required before a CME Certificate or Certificate of Attendance can be obtained.

Please answer all questions. For fields with no response, please mark N/A.
1. What is your degree? *
Please specify
2. On a scale of 1 - 5 with 1 = poor and 5= excellent, how would you rate this educational activity? *
3. As a result of this educational activity, I will change the way I practice with my patients. *
If yes, please cite 1 or more examples:
4. Do you feel that the information presented was based on the best scientific and rigorous evidence available? *
If no, explain:
5. Which of the following competency areas do you feel have been improved as a result of this activity? (Check all that apply) *
6. Do you feel each of the following learning objectives was met? 

I am now better able to:
Identify effective global lung cancer prevention strategies.
Improve my ability to participate in tobacco control and smoking cessation programs.
Describe the current approaches and strategies for early detection and screening of lung cancer.
Describe the best methods to implement multi-disciplinary tumor boards into community practices.
Describe evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
Describe evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
Recognize the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
Understand the molecular pathways that hold promise for therapeutic intervention.
Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
Describe current therapeutic approaches for patients with mesothelioma and thymoma.
Define optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
Describe the support and survivorship resources available for lung cancer patients and their families.
Illustrate important aspects of clinical trial design and master protocols.
Educate more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.
7. Did you feel that any speakers were biased in their presentation? *
If you marked “yes”, please check all of the categories you believe apply: *
Please explain: